Business Wire

Radisys Expands Access Portfolio with the Launch of Connect Open Broadband

21.5.2020 10:22:00 EEST | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today introduced Connect Open Broadband, a carrier-grade, Tier 1 network-hardened, scalable and secure software-defined Passive Optical Network (PON) distribution based on open standards and web-scale architecture to drive rapid innovation and economies of scale. The disaggregated PON solution gives Communications Service Providers (CSPs) deployment flexibility, scalable network growth, and increased service agility with optimized CapEx and OpEx.

News Highlights

  • The demand for high-speed broadband services such as internet, video calling and conferencing, and IPTV has created massive growth in network data usage like never before. As such, CSPs’ networks are increasingly overburdened. Service providers need to optimize their networks to scale service delivery efficiently, while maximizing the opportunity to deliver innovation at a rapid pace.
  • Radisys’ Connect Open Broadband offers an intelligent, scalable and secure software-defined PON distribution based on the Open Networking Foundation’s (ONF) SEBA reference platform and enhanced with Radisys innovation. This architecture allows for a seamless introduction of the Broadband Forum’s OB-BAA architecture by conforming to the standard YANG models with the Northbound Interface (NBI).
  • The solution disaggregates software from the underlying hardware with open interfaces, enabling faster product innovation cycles. The hardware agnostic solution enables service providers to leverage white-box optical line terminals (OLTs) from an interoperable multi-vendor ecosystem for flexible deployable options.
  • Connect Open Broadband, built on cloud-native microservices architecture, allows for the addition of new network functions on demand and delivers a path to automated and simplified network operation. The programmability, automation and deeper network visibility further enables better fault detection, faster service delivery and future-proof network expansions.
  • The solution is access network (GPON, XGS-PON, NG-PON2) agnostic and offers flexible deployment options.

“In the digital era where high-bandwidth services and pervasive connectivity are required to meet subscriber expectations, service providers are rethinking how they build their networks to meet demand with optimal performance and value,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Connect Open Broadband is a commercially ready, network-hardened solution that allows service providers to enable rapid innovation through disaggregation and to bring new services to market faster.”

“Radisys has been a Partner Member of ONF for many years and has been one of the most active supply chain members working directly with our operator partners. Radisys has helped drive ONF open reference designs and open source platforms and is among the first to commercialize solutions based on ONF platforms,” said Guru Parulkar, Executive Director, ONF. “Radisys’ Connect Open Broadband combines open architectures, software innovation, and white-box hardware to facilitate service agility.”

“Broadband service providers face increased pressure to deliver innovative services to compete with OTT providers,” said Simon Stanley, Analyst at Large, Heavy Reading. “Open, disaggregated solutions give service providers the flexibility to select best-in-class network elements from a number of vendors in order to intelligently scale their networks and deliver the services their customers demand in a cost-effective manner.”

Resources:

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release

Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I

Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release

Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye